- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Green Growth Brands (CSE:GGB, OTCQB:GGBXF) CEO Peter Horvath recently joined CNBC’s ‘Mad Money’ to discuss the growing CBD market.
Green Growth Brands (CSE:GGB, OTCQB:GGBXF) CEO Peter Horvath recently joined CNBC’s ‘Mad Money’ to discuss the growing CBD market.
During the feature, Horvath spoke with host Jim Cramer regarding the difference between CBD products and traditional cannabis products. The CBD market appears ready for significant growth, with industry experts like CNBC reporting the CBD industry has the potential to become a $22 billion market by 2022. This growth is expected to be driven by companies like Green Growth Brands, who have already opened 60 CBD-focused stores in the United States with another 170 expected to be opened over the next several months.
According to Horvath, the CBD market currently offers a more significant opportunity as US regulators have chosen to initially focus on the THC marketplace. “We’ve decided only to sell a topical product, which means it doesn’t get into your blood, which means the FDA isn’t as interested in it. People are selling inhalable and ingestible CBD and right now that’s federally illegal, per the FDA. That’s why we focused on topical,” said Horvath.
The company intends to leverage its experience in retail and personal healthcare products to create a comprehensive line of CBD products that are GMP-certified and fit for national distribution.
To watch the full interview between Horvath and CNBC’s Jim Cramer, click here.
Click here to connect with Green Growth Brands (CSE:GGB) for an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.